Online inquiry

IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5351MR)

This product GTTS-WQ5351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11388MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7682MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ12437MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ4925MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1341MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ10302MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ10439MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ5018MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW